BioSpace News Archive

CANTEL MEDICAL CORP. will release the results for its fourth quarter ended July 31, 2020 on Thursday, September 17, 2020 before the market opens, and hold a conference call to discuss the results at 8:30 a.m. ET.

Sutro Biopharma, Inc. announced that Bill Newell, Chief Executive Officer, will present at the following investor conferences in September

Phosplatin Therapeutics announced that new clinical data from a dose escalation study of lead candidate PT-112, an immunogenic cell death inducer, used in combination with PD-L1 checkpoint inhibitor avelumab, will be presented at the upcoming European Society for Medical Oncology Virtual Congress 2020 taking place September 19-21.

Lodo Expands Its Preclinical Pipeline with Selective Proteasome Inhibitors with Potential Application in Solid Tumor Cancers and Other Indications

Boston Scientific announced that the U.S. Centers for Medicare and Medicaid Services granted a New Technology Add-on Payment for the Eluvia™ Drug-Eluting Vascular Stent System as part of the 2021 Inpatient Prospective Payment System.

Ionis Pharmaceuticals, Inc., the leader in antisense therapeutics, announced that management will present a company overview at the following virtual investor conferences

AVEO Oncology announced that Michael Bailey, president and chief executive officer of AVEO, will participate in two upcoming virtual investor conferences

Rallybio, a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, announced that it has appointed Helen M. Boudreau, former Chief Operating Officer of the Bill & Melinda Gates Medical Research Institute, to its Board of Directors.

Bicycle Therapeutics plc, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide technology, announced that management will participate in the following virtual investor conferences in September:

Ocular Therapeutix, Inc. a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced that it will present and host investor meetings at the following conferences:.